A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy

American Journal of Hematology

Volumn 92, Issue 12, 2017, Pages 1333-1339

  Estepp, Jeremie H ^a   Smeltzer, Matthew P ^b   Kang, Guolian ^a   Li, Chen ^a   Wang, Winfred C ^a   Abrams, Christina ^c   Aygun, Banu ^d   Ware, Russell E ^e   Nottage, Kerri ^f   Hankins, Jane S ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF MEMPHIS   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d Northwell Health   (United States)

^e CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^f JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN F; HYDROXYUREA; ANTISICKLING AGENT;

ACUTE CHEST SYNDROME; ARTICLE; BACTERIAL INFECTION; BLOOD VESSEL OCCLUSION; CHILD; CHILD HOSPITALIZATION; CLINICAL OUTCOME; CLINICAL TRIAL; COHORT ANALYSIS; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFECT; FEMALE; FEVER; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HOSPITAL READMISSION; HUMAN; LABORATORY TEST; LEUKOCYTE COUNT; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MEAN CORPUSCULAR VOLUME; MEDICATION COMPLIANCE; NEUTROPENIA; NEUTROPHIL COUNT; OBSERVATIONAL STUDY; PAIN; PATIENT COMPLIANCE; PHARMACEUTICAL CARE; PRESCHOOL CHILD; PRIORITY JOURNAL; RETICULOCYTE COUNT; SICKLE CELL ANEMIA; SICKLE CELL BETA THALASSEMIA; SIDE EFFECT; THROMBOCYTE COUNT; ADOLESCENT; BLOOD; BLOOD CELL COUNT; COMPLICATION; DOSE RESPONSE; DRUG EFFECTS; HOSPITALIZATION; INFANT; PROSPECTIVE STUDY; STANDARDS;

ADOLESCENT; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; BLOOD CELL COUNT; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FETAL HEMOGLOBIN; HOSPITALIZATION; HUMANS; HYDROXYUREA; INFANT; MALE; MAXIMUM TOLERATED DOSE; PROSPECTIVE STUDIES;

EID: 85030630188     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24906     Document Type: Article

References (45)

1. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;330(23):1639–1644.
2. Akinsheye I, Alsultan A, Solovieff N, et al. Fetal hemoglobin in sickle cell anemia. Blood. 2011;118(1):19–27.
3. Leikin SL, Gallagher D, Kinney TR, Sloane D, Klug P, Rida W. Mortality in children and adolescents with sickle cell disease. Cooperative Study of Sickle Cell Disease. Pediatrics. 1989;84(3):500–508.
4. Stevens MC, Hayes RJ, Vaidya S, Serjeant GR. Fetal hemoglobin and clinical severity of homozygous sickle cell disease in early childhood. J Pediatr. 1981;98(1):37–41.
5. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med. 1991;325(1):11–16.
6. Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: Summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312(10):1033–1048.
7. Hankins JS, Ware RE, Rogers ZR, et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: The HUSOFT extension study. Blood. 2005;106(7):2269–2275.
8. Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: A multicentre, randomised, controlled trial (BABY HUG). Lancet. 2011;377(9778):1663–1672.
9. Zimmerman SA, Schultz WH, Davis JS, et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood. 2004;103(6):2039–2045.
10. Lobo CL, Pinto JF, Nascimento EM, Moura PG, Cardoso GP, Hankins JS. The effect of hydroxcarbamide therapy on survival of children with sickle cell disease. Br J Haematol. 2013;161(6):852–860.
11. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: Risks and benefits up to 9 years of treatment. JAMA. 2003;289(13):1645–1651.
12. Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: Results of a 17-year, single-center trial (LaSHS). Blood. 2010;115(12):2354–2363.
13. Wiczling P, Liem RI, Panepinto JA, et al. Population pharmacokinetics of hydroxyurea for children and adolescents with sickle cell disease. J Clin Pharmacol. 2014;54(9):1016–1022.
14. Estepp JH, Melloni C, Thornburg CD, et al. Best pharmaceuticals for children act-pediatric trials network administrative core committee. J Clin Pharmacol. 2016;56(3):298–306.
15. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995;332(20):1317–1322.
16. Ware RE, Davis BR, Schultz WH, et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): A multicentre, open-label, phase 3, non-inferiority trial. Lancet. 2016;387(10019):661–670.
17. Lebensburger JD, Pestina TI, Ware RE, Boyd KL, Persons DA. Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model. Haematologica. 2010;95(9):1599–1603.
18. Kinney TR, Helms RW, O'branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood. 1999;94(5):1550–1554.
19. Pestina TI, Hargrove PW, Zhao H, et al. Amelioration of murine sickle cell disease by nonablative conditioning and gamma-globin gene-corrected bone marrow cells. Mol Ther Methods Clin Dev. 2015;2:15045.
20. Steinberg MH, Chui DH, Dover GJ, Sebastiani P, Alsultan A. Fetal hemoglobin in sickle cell anemia: A glass half full?. Blood. 2014;123(4):481–485.
21. Powars DR, Weiss JN, Chan LS, Schroeder WA. Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia? Blood. 1984;63(4):921–926.
22. Bhatnagar P, Keefer JR, Casella JF, et al. Association between baseline fetal hemoglobin levels and incidence of severe vaso-occlusive pain episodes in children with sickle cell anemia. Pediatr Blood Cancer. 2013;60(10):E125–E127.
23. Heeney MM, Ware RE. Hydroxyurea for children with sickle cell disease. Hematol Oncol Clin North Am. 2010;24(1):199–214.
24. Ballas SK, Lieff S, Benjamin LJ, et al. Definitions of the phenotypic manifestations of sickle cell disease. Am J Hematol. 2010;85(1):6–13.
25. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidem Drug Safe. 2006;15(8):565–574. discussion 575-567.
26. Grosset KA, Bone I, Grosset DG. Suboptimal medication adherence in Parkinson's disease. Mov Disord. 2005;20(11):1502–1507.
27. Rosen MI, Rigsby MO, Salahi JT, Ryan CE, Cramer JA. Electronic monitoring and counseling to improve medication adherence. Behav Res Ther. 2004;42(4):409–422.
28. Candrilli SD, O'brien SH, Ware RE, Nahata MC, Seiber EE, Balkrishnan R. Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease. Am J Hematol. 2011;86(3):273–277.
29. Estepp JH, Winter B, Johnson M, Smeltzer MP, Howard SC, Hankins JS. Improved hydroxyurea effect with the use of text messaging in children with sickle cell anemia. Pediatr Blood Cancer. 2014;61(11):2031–2036.
30. Ware RE, Aygun B. Advances in the use of hydroxyurea. Hematology American Society of. Hematol Educ Program. 2009;62–69.
31. Nottage KA, Ware RE, Aygun B, et al. Hydroxycarbamide treatment and brain MRI/MRA findings in children with sickle cell anaemia. Br J Haematol. 2016;175(2):331–338.
32. Nottage KA, Ware RE, Winter B, et al. Predictors of splenic function preservation in children with sickle cell anemia treated with hydroxyurea. Eur J Haematol. 2014;93(5):377–383.
33. Aygun B, Mortier NA, Smeltzer MP, Shulkin BL, Hankins JS, Ware RE. Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell anemia. Am J Hematol. 2013;88(2):116–119.
34. Aygun B, Mortier NA, Smeltzer MP, Hankins JS, Ware RE. Glomerular hyperfiltration and albuminuria in children with sickle cell anemia. Pediatr Nephrol. 2011;26(8):1285–1290.
35. Ferster A, Tahriri P, Vermylen C, et al. Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood. 2001;97(11):3628–3632.
36. Gulbis B, Haberman D, Dufour D, et al. Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: The Belgian experience. Blood. 2005;105(7):2685–2690.
37. Steinberg MH, Lu ZH, Barton FB, Terrin ML, Charache S, Dover GJ. Fetal hemoglobin in sickle cell anemia: Determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea. Blood. 1997;89(3):1078–1088.
38. Marcus SJ, Ware RE. Physiologic decline in fetal hemoglobin parameters in infants with sickle cell disease: Implications for pharmacological intervention. J Pediatr Hematol Oncol. 1999;21(5):407–411.
39. Marcus SJ, Kinney TR, Schultz WH, O'branski EE, Ware RE. Quantitative analysis of erythrocytes containing fetal hemoglobin (F cells) in children with sickle cell disease. Am J Hematol. 1997;54(1):40–46.
40. Brousseau DC, Owens PL, Mosso AL, Panepinto JA, Steiner CA. Acute care utilization and rehospitalizations for sickle cell disease. JAMA. 2010;303(13):1288–1294.
41. Ataga KI, Kutlar A, Kanter J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017;376(5):429–439.
42. Oder E, Safo MK, Abdulmalik O, Kato GJ. New developments in anti-sickling agents: Can drugs directly prevent the polymerization of sickle haemoglobin in vivo?. Br J Haematol. 2016;175(1):24–30.
43. Almeida CB, Souza LE, Leonardo FC, et al. Acute hemolytic vascular inflammatory process are prevented by nitric oxide replacement or a single dose of hydroxyurea. Blood. 2017;126(6):711–720.
44. Ware RE. How I use hydroxyurea to treat young patients with sickle cell anemia. Blood. 2010;115(26):5300–5311.
45. Brown AK, Sleeper LA, Miller ST, Pegelow CH, Gill FM, Waclawiw MA. Reference values and hematologic changes from birth to 5 years in patients with sickle cell disease. Cooperative Study of Sickle Cell Disease. Arch Pediatr Adolesc Med. 1994;148(8):796–804.